IP Library Granted Patent US 10,064,859
Granted Patent B2
US 10,064,859 · App. 14/833,638 · Granted Sep 4, 2018

Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,859
App. No.
14/833,638
Granted
Sep 4, 2018
Kind
B2
Abstract

Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m 2 /g; and crystals of aripiprazole lauroxil produced by such processes.

Claims (26)

1. A process for making the compound of Formula (I) in crystal form

the process comprising the steps of:

(a) dissolving the compound of Formula (I) or a salt or solvate thereof in a first solvent to form a homogeneous drug solution;

(b) optionally combining the drug solution with a second solvent;

(c) cooling the solution; and

(d) when the temperature of the solution is within the range of about 31-38° C., inducing formation of crystallized particles of the compound of Formula (I) from the homogeneous solution with a homogenizer, the crystallized particles having a surface area of about 0.50 to about 3.3 m 2 /g.

2. The process of claim 1 , further comprising the steps of:

(e) stopping the homogenizer, and re-dissolving the crystallized particles of the compound of Formula (I) by heating the solution;

(f) cooling the solution; and

(g) when the temperature of the solution is within the range of about 31-38° C., inducing formation of crystallized particles of the compound of Formula (I) from the homogeneous solution with a homogenizer, the crystallized particles having a surface area of about 0.50 to about 3.3 m 2 /g.

3. The process of claim 1 , wherein the crystallized particles have a surface area of about 0.80 to about 1.1 m 2 /g.

4. The process of claim 1 , wherein the crystallized particles have a surface area of about 1.00 m 2 /g.

5. The process of claim 1 , wherein the Dv[50] of the crystallized particles is about 10 to about 30 microns.

6. The process of claim 5 , wherein the Dv[50] of the crystallized particles is about 10 to about 20 microns.

7. The process of claim 1 , wherein the first solvent is isopropyl acetate.

8. The process of claim 1 , wherein the first solvent is a mixture of isopropyl acetate and n-heptane.

9. The process of claim 1 , wherein the second solvent is n-heptane.

10. The process of claim 1 , wherein in step (b), the temperature of the solution is in the range of about 55° C. to about 65° C.

11. The process of claim 1 , wherein in step (d), the temperature of the solution is about 34° C.

12. The process of claim 1 , wherein one or more of steps (a) through (c) is performed under agitation.

13. The process of claim 2 , wherein one or more of steps (a), (b), (c), (d), (e), (f), and (g) is performed under agitation.

14. The process of claim 1 , further comprising the step of filtering the crystallized particles.

15. The process of claim 14 , further comprising the step of rinsing the crystallized particles.

16. The process of claim 15 , further comprising the step of drying the crystallized particles.

17. The process of claim 1 , wherein the temperature of the solution in step (d) is within the range of about 31-35° C.

18. The process of claim 2 , wherein the temperature of the solution in step (g) is within the range of about 31-35° C.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENTS Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2018
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 046214/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2016
From: MORALES, WILFREDO, JR.; ZEIDAN, TAREK A.; CHIARELLA, RENATO A.; WRIGHT, STEVEN G.; PERRY, JASON M.
To: ALKERMES, INC.
Reel/Frame 038728/0338 →